Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Improved profit margins, primarily resulting from sales price revisions, and recognition of a gain on the sale of investment securities as extraordinary income. For the fiscal year ending March 2027, the Company expects lower revenue and lower profits due to a decline in products in the Synthesis segment and the non-recurring benefit of the previous fiscal year's sales price revision.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥28,858 million (YoY +1.2%) |
| Operating profit | ¥2,050 million (YoY +32.2%) |
| Ordinary income | ¥2,104 million (YoY +33.1%) |
| Profit attributable to owners of the parent | ¥1,852 million (YoY +121.7%) |
| Net income per share | ¥59.41 |
| Operating Margin | 7.1% |
| Equity ratio | End of the current fiscal period 68.1% / End of previous period 64.7% |
| Total assets | ¥36,885 million |
| Net assets | ¥25,120 million |
| Cash flows from operating activities | ¥4,483 million |
| Cash flows from investing activities | ¥-74 million |
| Cash flows from financing activities | ¥-661 million |
| Cash and cash equivalents at end of period | ¥8,005 million |
| Full-year earnings forecast | Net Sales ¥25,600 million (YoY -11.3%) / Operating profit ¥1,450 million (YoY -29.3%) / Ordinary income ¥1,500 million (YoY -28.7%) / Net income ¥1,850 million (YoY -0.1%) |
| Annual Dividend Forecast | ¥13 → ¥10（-23.1%） |
| Payout ratio | 16.6 |
| Shareholder Return Policy | The Company targets an annual consolidated dividend payout ratio of approximately 30% and sets an annual dividend of ¥10 per share as the minimum during the period covered by the medium-term management plan through fiscal 2030. |
| Depreciation and amortization | ¥653 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥768,193 thousand, Gain on sale of non-current assets ¥504 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥16,513 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 31,530,000 shares |
| Treasury Shares at Period-End | 895,101 shares |
| Factors Behind Changes in Business Performance | Improved profit margins, primarily resulting from sales price revisions, and recognition of a gain on the sale of investment securities as extraordinary income. For the fiscal year ending March 2027, the Company expects lower revenue and lower profits due to a decline in products in the Synthesis segment and the non-recurring benefit of the previous fiscal year's sales price revision. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, operating income and ordinary income increased due to improved profit margins, primarily resulting from sales price revisions. The recognition of a gain on the sale of investment securities as extraordinary income also boosted net income. For the fiscal year ending March 2027, the Company expects lower revenue and lower profits, primarily due to a decline in products in the Synthesis segment and the non-recurring benefit of improved profit margins from the previous fiscal year's sales price revisions.